Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a... Aliment Pharmacol Ther 2010; 32: 522–528 Summary Background Randomized, controlled trials have demonstrated that anti‐TNF agents are efficacious in inducing remission in cases of Crohn’s disease and ulcerative colitis. However, response rates for anti‐TNF agents in ‘real life’ clinical practice are less well‐defined. Aims To examine the response rates and long‐term outcomes of infliximab and adalimumab treatment for out‐patients with ulcerative colitis and to study the variables associated with response rates. Methods In a prospective study, a single‐centre out‐patient cohort was treated and followed up according to a structured protocol of clinical care. Response to treatment was assessed using a physician’s global assessment that focused on normalization of bowel frequency, absence of blood with defecation and tapering of corticosteroids to zero. Results Fifty‐three ulcerative colitis patients were included in the study. Responses to induction therapy were 96.4% (27/28) for infliximab and 80% (20/25) for adalimumab (P = 0.0889). Responses to maintenance therapy were similar: infliximab 77.8% (14/18) and adalimumab 70.0% (14/20) (P = 0.7190). Multivariate analyses of the induction and maintenance responses did not reveal confounding elements. No new safety signals were identified. Conclusions This long‐term follow‐up of a single‐centre cohort of ulcerative colitis patients demonstrates that ‘real‐life’ out‐patient treatment with infliximab and adalimumab is effective in induction and maintenance of response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alimentary Pharmacology & Therapeutics Wiley

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort

Download PDF
7 pages

Loading next page...
 
/lp/wiley/treatment-of-ulcerative-colitis-with-adalimumab-or-infliximab-long-XTLVyTqTji

References (19)

Publisher
Wiley
Copyright
© 2010 Blackwell Publishing Ltd
ISSN
0269-2813
eISSN
1365-2036
DOI
10.1111/j.1365-2036.2010.04380.x
pmid
20500733
Publisher site
See Article on Publisher Site

Abstract

Aliment Pharmacol Ther 2010; 32: 522–528 Summary Background Randomized, controlled trials have demonstrated that anti‐TNF agents are efficacious in inducing remission in cases of Crohn’s disease and ulcerative colitis. However, response rates for anti‐TNF agents in ‘real life’ clinical practice are less well‐defined. Aims To examine the response rates and long‐term outcomes of infliximab and adalimumab treatment for out‐patients with ulcerative colitis and to study the variables associated with response rates. Methods In a prospective study, a single‐centre out‐patient cohort was treated and followed up according to a structured protocol of clinical care. Response to treatment was assessed using a physician’s global assessment that focused on normalization of bowel frequency, absence of blood with defecation and tapering of corticosteroids to zero. Results Fifty‐three ulcerative colitis patients were included in the study. Responses to induction therapy were 96.4% (27/28) for infliximab and 80% (20/25) for adalimumab (P = 0.0889). Responses to maintenance therapy were similar: infliximab 77.8% (14/18) and adalimumab 70.0% (14/20) (P = 0.7190). Multivariate analyses of the induction and maintenance responses did not reveal confounding elements. No new safety signals were identified. Conclusions This long‐term follow‐up of a single‐centre cohort of ulcerative colitis patients demonstrates that ‘real‐life’ out‐patient treatment with infliximab and adalimumab is effective in induction and maintenance of response.

Journal

Alimentary Pharmacology & Therapeutics – Wiley

Published: Aug 1, 2010

There are no references for this article.